Halozyme Therapeutics Elects Dannielle Appelhans to Board

What Happened
Halozyme Therapeutics, Inc. (HALO) filed a Form 8-K (Item 5.02) reporting that Dannielle Appelhans was elected to the company’s Board of Directors on August 14, 2026. Ms. Appelhans was placed in the class of directors with a term ending at the Company’s annual meeting of stockholders in 2028. She was not initially assigned to any Board committee.

Key Details

• Election date: August 14, 2026; 8-K filed August 18, 2026.
• Term: Member of the director class with term expiring at the 2028 annual meeting.
• Committee assignment: None at the time of appointment.
• Compensation: Will receive standard non-employee director compensation (cash retainers, restricted stock, stock option awards) under Halozyme’s director compensation program as described in the company’s 2026 proxy (May 5, 2026).
• Conflicts: Company reported no arrangements related to her election and no related person transactions between Ms. Appelhans and Halozyme.

Why It Matters
Board additions affect company oversight and governance. This filing confirms a new independent director has been added with standard compensation and no disclosed related-party ties, which may be relevant to investors assessing governance and potential conflicts of interest.